We’re tracking in-house compensation. Take the Law360 Survey
Click here
October 18, 2004
IN RE: Merck & Co., Inc., Securities, Derivative & "ERISA" Litigation
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
May 13, 2015
A New Jersey federal judge ruled Wednesday that a class alleging securities fraud could not prove Merck & Co. Inc. misrepresented Vioxx's heart attack risks at least prior to a study comparing the arthritis medication with another leading drug, but could still prove Merck misled investors after learning of the study results.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Get instant access to the one-stop news source for business lawyers
Register Now!
Sign up now for free access to this content